pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
476
stories
Sep 8, 26
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
biospace
Sep 8, 26
STAT+: Oura files to goes public, reported $1.2B in earnings
stat
Sep 8, 26
STAT+: FDA approves AstraZeneca breast cancer drug
stat
Sep 8, 26
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
stat
Sep 8, 26
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
biospace
Sep 8, 26
STAT+: Inhibrx claims first win for long-sought immunotherapy target
stat
Sep 8, 26
STAT+: Roivant lung disease drug hits mid-stage study goals
stat
Sep 8, 26
STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
stat
Sep 7, 26
Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly
endpoints
Sep 7, 26
STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
stat
Sep 7, 26
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
fiercebiotech
Sep 7, 26
Updated: Novo Nordisk cans two more trials of IL-6 heart drug for futility
endpoints
Sep 5, 26
Opinion: What STAT readers think about M.D. vs. D.O., AI in medicine, surrogacy, and more
stat
Sep 4, 26
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
stat
Sep 4, 26
Menarini signs $771M deal to take Gan & Lee GLP-1 to European market
fiercebiotech
Sep 3, 26
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
fiercebiotech
Sep 3, 26
STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
stat
Sep 2, 26
Building the Data Foundation for AI-Driven Clinical Development
fiercebiotech
Sep 2, 26
UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy
endpoints
Sep 2, 26
Doctors groups release vaccination guidelines ahead of respiratory illness season
stat
Sep 2, 26
STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
stat
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Aug 29, 26
#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo's failure
endpoints
Aug 28, 26
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
biopharma dive
Aug 28, 26
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
biospace
Aug 28, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more
stat
Aug 28, 26
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
endpoints
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 26, 26
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
biospace
Aug 26, 26
Boston Scientific hit by cyberattack causing ‘disruptions’ to parts of its business
fiercebiotech
← prev
page 8 of 16
next →
